单关节炎揭示克罗恩病中英夫利昔单抗诱导的系统性红斑狼疮

MOJ orthopedics & rheumatology Pub Date : 2019-01-01 DOI:10.15406/mojor.2019.11.00495

S. Bouomrani, F. Rekik, Ali Naffati, W. Mahdhaoui, A. Hammami, Dhia Eddine Amri

{"title":"单关节炎揭示克罗恩病中英夫利昔单抗诱导的系统性红斑狼疮","authors":"S. Bouomrani, F. Rekik, Ali Naffati, W. Mahdhaoui, A. Hammami, Dhia Eddine Amri","doi":"10.15406/mojor.2019.11.00495","DOIUrl":null,"url":null,"abstract":"Infliximab, a chimeric monoclonal antibody, is an anti-tumor necrosis factor alpha (anti-TNFα) that is increasingly used for the treatment of severe and resistant forms of inflammatory bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)).1,2 It is characterized by its efficiency and good tolerance.2 Induced systemic lupus erythematosus (SLE) remains an exceptional but potentially serious complication of this biological treatment.1,2","PeriodicalId":91366,"journal":{"name":"MOJ orthopedics & rheumatology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monoarthritis revealing Infliximab-induced systemic lupus erythematosus in Crohn's disease\",\"authors\":\"S. Bouomrani, F. Rekik, Ali Naffati, W. Mahdhaoui, A. Hammami, Dhia Eddine Amri\",\"doi\":\"10.15406/mojor.2019.11.00495\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Infliximab, a chimeric monoclonal antibody, is an anti-tumor necrosis factor alpha (anti-TNFα) that is increasingly used for the treatment of severe and resistant forms of inflammatory bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)).1,2 It is characterized by its efficiency and good tolerance.2 Induced systemic lupus erythematosus (SLE) remains an exceptional but potentially serious complication of this biological treatment.1,2\",\"PeriodicalId\":91366,\"journal\":{\"name\":\"MOJ orthopedics & rheumatology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MOJ orthopedics & rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/mojor.2019.11.00495\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MOJ orthopedics & rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/mojor.2019.11.00495","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

英夫利昔单抗是一种嵌合单克隆抗体，是一种抗肿瘤坏死因子α (anti-TNFα)，越来越多地用于治疗严重和耐药形式的炎症性肠病(克罗恩病(CD)和溃疡性结肠炎(UC))。它的特点是效率高，耐受性好诱导性系统性红斑狼疮(SLE)仍然是这种生物治疗的一种特殊但潜在的严重并发症

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Monoarthritis revealing Infliximab-induced systemic lupus erythematosus in Crohn's disease

Infliximab, a chimeric monoclonal antibody, is an anti-tumor necrosis factor alpha (anti-TNFα) that is increasingly used for the treatment of severe and resistant forms of inflammatory bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)).1,2 It is characterized by its efficiency and good tolerance.2 Induced systemic lupus erythematosus (SLE) remains an exceptional but potentially serious complication of this biological treatment.1,2

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

MOJ orthopedics & rheumatology

自引率

0.00%

发文量